Combined Maximum Tolerated Activity and Lesion-based Dosimetry for Personalized Radioiodine Therapy in Metastatic Differentiated Thyroid Carcinoma: An Early Institutional Experience

Objectives

Empirical fixed-activity radioiodine (RAI) therapy remains widely used in differentiated thyroid carcinoma (DTC), despite substantial inter-patient variability in iodine kinetics. Pre-therapeutic dosimetry offers a personalised approach by estimating radiation exposure to organs at risk as well as to tumour lesions. To describe our institutional experience with combined maximum tolerated activity (MTA) and lesion-based dosimetry in patients with metastatic or recurrent DTC, and to evaluate its impact on clinical decision-making.